Συγγραφείς:
Ziogas, D.C.
Terpos, E.
Gavriatopoulou, M.
Migkou, M.
Fotiou, D.
Roussou, M.
Kanellias, N.
Tatouli, I.
Eleutherakis-Papaiakovou, E.
Panagiotidis, I.
Ntanasis-Stathopoulos, I.
Kastritis, E.
Dimopoulos, M.A.
Λέξεις-κλειδιά:
ADP ribosyl cyclase/cyclic ADP ribose hydrolase 1; amphotericin B lipid complex; bortezomib; C reactive protein; daratumumab; dexamethasone; elotuzumab; lenalidomide; M protein; masitinib; melphalan; monoclonal antibody; piperacillin plus tazobactam; placebo; recombinant granulocyte colony stimulating factor; thalidomide; zoledronic acid; antineoplastic agent; antiprotozoal agent; CD38 protein, human; membrane protein; signaling lymphocytic activation molecule; SLAMF7 protein, human, abdominal radiography; aged; amastigote; autologous stem cell transplantation; backache; bone atrophy; bone marrow biopsy; cancer combination chemotherapy; cancer recurrence; case report; clinical article; clinical examination; comorbidity; computer assisted tomography; drug megadose; febrile neutropenia; female; fever; human; laboratory test; Letter; male; multiple cycle treatment; multiple myeloma; night sweat; opportunistic infection; palliative therapy; pancytopenia; priority journal; protein urine level; radiation dose fractionation; splenomegaly; systemic therapy; treatment response; urinary excretion; visceral leishmaniasis; antagonists and inhibitors; immunocompromised patient; immunology; immunosuppressive treatment; isolation and purification; Leishmania donovani; multiple myeloma; opportunistic infection; parasitology; procedures; recurrent disease; visceral leishmaniasis, ADP-ribosyl Cyclase 1; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiprotozoal Agents; Female; Humans; Immunocompromised Host; Immunosuppression; Leishmania donovani; Leishmaniasis, Visceral; Male; Membrane Glycoproteins; Multiple Myeloma; Opportunistic Infections; Recurrence; Signaling Lymphocytic Activation Molecule Family
